Eli Lilly (LLY) shares spiked ~3% on Thursday after the obesity drugmaker posted Phase 3 data showing its next-gen therapy retatrutide can generate up to 24% of weight loss, a “best-in-class" efficacy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback